| Trial registration number
|
NCT05246072 |
Full text link
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
https://clinicaltrials.gov/show/NCT05246072
|
First author
Last imported at : April 8, 2022, 9:30 p.m.
Source : ClinicalTrials.gov
|
Not reported
|
Contact
Last imported at : April 8, 2022, 9:30 p.m.
Source : ClinicalTrials.gov
|
Not reported
|
Registration date
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
2022-02-18
|
Recruitment status
Last imported at : April 8, 2022, 9:30 p.m.
Source : ClinicalTrials.gov
|
Completed
|
Study design
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
RCT
|
Allocation
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Randomized
|
Design
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Parallel
|
Masking
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Open label
|
Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov
|
single-center
|
Study aim
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Treatment
|
Inclusion criteria
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
inclusion criteria:
willing and able to provide written informed consent prior to performing study procedures.
currently hospitalized and requiring medical care for non-sever covid-19.
one or more of the following: (positive pcr test or positive antibodies) or (ct chest consistent with covid19 infection).
|
Exclusion criteria
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
tocilizumab use.
mechanical ventilation
requirement of oxygen supplementation >8l/min on admission
|
Number of arms
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
3
|
Funding
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Ain Shams University
|
Inclusion age min
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
18
|
Inclusion age max
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
80
|
Countries
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Egypt
|
Type of patients
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Moderate disease at enrollment
|
Severity scale
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
3: Moderate disease at enrollment
|
Total sample size
Last imported at : April 8, 2022, 9:30 p.m.
Source : ClinicalTrials.gov
|
135
|
primary outcome
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
length of oxygen requirement
|
Notes
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
None
|
Phase
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
Phase 4
|
Arms
Last imported at : Feb. 19, 2022, 5 p.m.
Source : ClinicalTrials.gov
|
[{"arm_notes": "", "treatment_id": 2197, "treatment_name": "Colchicine+ivermectin", "treatment_type": "Metabolic agents+antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 310, "treatment_name": "Colchicine", "treatment_type": "Metabolic agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]
|